KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Intangibles (2016 - 2022)

Ionis Pharmaceuticals (IONS) has 14 years of Intangibles data on record, last reported at $29.6 million in Q3 2022.

  • For Q3 2022, Intangibles fell 1.44% year-over-year to $29.6 million; the TTM value through Sep 2022 reached $29.6 million, down 1.44%, while the annual FY2021 figure was $29.0 million, 3.82% up from the prior year.
  • Intangibles reached $29.6 million in Q3 2022 per IONS's latest filing, up from $29.1 million in the prior quarter.
  • Across five years, Intangibles topped out at $30.0 million in Q3 2021 and bottomed at $22.9 million in Q1 2018.
  • Average Intangibles over 5 years is $27.1 million, with a median of $27.7 million recorded in 2020.
  • Peak YoY movement for Intangibles: rose 12.31% in 2019, then decreased 1.44% in 2022.
  • A 5-year view of Intangibles shows it stood at $24.0 million in 2018, then rose by 6.83% to $25.7 million in 2019, then grew by 8.81% to $27.9 million in 2020, then rose by 3.82% to $29.0 million in 2021, then increased by 2.07% to $29.6 million in 2022.
  • Per Business Quant database, its latest 3 readings for Intangibles were $29.6 million in Q3 2022, $29.1 million in Q2 2022, and $29.3 million in Q1 2022.